top of page
Qubigen and University of Melbourne Secure Federal AEA Grant to Advance AI-Driven Drug Design
Qubigen is proud to announce the successful award of an Australian Government Australia’s Economic Accelerator (AEA) Ignite grant in partnership with the University of Melbourne, supporting a ground-breaking project at the intersection of artificial intelligence and medical science. The project, “AI-Driven Drug Discovery for Next-Generation STING Inhibitors” has been awarded $496,348 in federal funding and will accelerate the development of novel therapeutics for neuroinflamm
Feb 132 min read
One Year of Qubigen: From Federated AI Vision to Scalable Drug Design Reality
As Qubigen approaches the end of 2025, we mark an important milestone: our first year of operation. In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value across the life sciences ecosystem. This first year has been defined by three converging forces: strong technical performance, globa
Dec 23, 20254 min read
Qubigen to Attend JPM Week 2026 in San Francisco, Engaging Investors & Exploring Strategic Partnerships
Qubigen is pleased to announce its participation at JPM Week 2026 in San Francisco, the premier global gathering for biotech, pharma, medtech, and life sciences investment. JPM Week sees hundreds of industry leaders, investors, innovators and entrepreneurs convene each January in San Francisco, offering a unique moment to build partnerships, explore business development and invest in the future of healthcare innovation. Qubigen Attendees Representing Qubigen at JPM Week wil
Dec 2, 20252 min read
bottom of page